A number of reports have also indicated that high expression of MCL‐1 is responsible for nonremission following venetoclax treatment, and combined treatment with an MCL‐1 inhibitor can reverse the original resistance in AML cells. This evidence concerns the gene MCL1 and acute myeloid leukemia.